stoxline Quote Chart Rank Option Currency Glossary
  
Qualigen Therapeutics, Inc. (QLGN)
3.87  -0.07 (-1.78%)    05-16 16:00
Open: 3.97
High: 4.1199
Volume: 37,970
  
Pre. Close: 3.94
Low: 3.75
Market Cap: 3(M)
Technical analysis
2025-05-16 4:42:55 PM
Short term     
Mid term     
Targets 6-month :  5.13 1-year :  6
Resists First :  4.4 Second :  5.13
Pivot price 3.62
Supports First :  3.44 Second :  2.84
MAs MA(5) :  3.78 MA(20) :  3.63
MA(100) :  3.53 MA(250) :  6.62
MACD MACD :  0.1 Signal :  0
%K %D K(14,3) :  83.1 D(3) :  70.5
RSI RSI(14): 62
52-week High :  29.45 Low :  2.84
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ QLGN ] has closed below upper band by 5.9%. Bollinger Bands are 32.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.12 - 4.14 4.14 - 4.16
Low: 3.7 - 3.73 3.73 - 3.75
Close: 3.83 - 3.87 3.87 - 3.9
Company Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Headline News

Thu, 01 May 2025
Nasdaq Threatens to Delist Qualigen on May 5: Company Plans Last-Minute Appeal - Stock Titan

Thu, 01 May 2025
Qualigen Therapeutics, Inc. Receives Notification of - GlobeNewswire

Tue, 01 Apr 2025
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire

Tue, 01 Apr 2025
Qualigen Therapeutics Delays Yearly Financial Report - TipRanks

Tue, 01 Apr 2025
Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com

Thu, 05 Dec 2024
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 1 (M)
Held by Insiders 735990 (%)
Held by Institutions 3.7 (%)
Shares Short 120 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 3
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -126.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -2.31818e+007
Sales Per Share 0
EBITDA (p.s.) -6.26364e+007
Qtrly Earnings Growth 635 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio 1.28
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.03
Stock Dividends
Dividend 0
Forward Dividend 44740
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android